For decades, the medical community’s approach to menopausal hormone therapy (MHT) has been shrouded in caution, largely shaped by the landmark Women’s Health Initiative (WHI) study released over twenty years ago. The findings from that era—suggesting that hormone replacement might increase risks of cardiovascular disease (CVD), breast cancer, and dementia—led to a sharp decline in prescriptions and a lingering fear among both patients and physicians.
However, a new, large-scale target trial emulation study published in JAMA Internal Medicine is challenging the "one-size-fits-all" narrative. By analyzing data from the Study of Women’s Health Across the Nation (SWAN), researchers have found that for specific groups of women, MHT may actually offer cardiovascular benefits, provided the therapy is initiated at the right time.
The Core Findings: Timing is Everything
Led by Samar El Khoudary, PhD, MPH, of the Virginia Commonwealth University School of Public Health, the research team sought to untangle the complex relationship between hormone therapy and heart health. By emulating a series of clinical trials using long-term observational data, the study focused on perimenopausal and recently postmenopausal women who had no prior history of cardiovascular disease.
The headline finding is striking: Among the study cohort, the initiation of MHT was associated with a 22% reduction in cardiovascular events (adjusted hazard ratio [aHR] 0.78). However, this benefit was not distributed equally across the participant population.
The most significant protective effect—a 27% reduction in CVD risk—was observed in women who initiated MHT within 10 years of the onset of menopause. Conversely, for those who started hormone therapy more than a decade after menopause began, the study found no cardiovascular benefit, with an aHR of 1.53, suggesting that the "window of opportunity" for heart protection may be narrow and time-sensitive.
Chronology: From the WHI Legacy to the Present
To understand the weight of this new study, one must look at the timeline of MHT research:
- The Early 2000s: The Women’s Health Initiative (WHI) was halted early after findings indicated that combined estrogen and progestin therapy increased the risk of breast cancer and cardiovascular events in postmenopausal women. These results led to the introduction of black-box warnings on hormone therapy products.
- The Mid-2010s: As more data emerged, experts began to suggest that the age of the participants in the original WHI study—many of whom were well past menopause—might have skewed the results. This gave rise to the "timing hypothesis," which posits that hormone therapy is safer and more effective when started during the early stages of the menopausal transition.
- 2024: The FDA officially updated the labeling for several hormone replacement therapies, removing the broad boxed warnings for cardiovascular disease, breast cancer, and dementia that had stood for over two decades. This move reflected a more nuanced understanding of the risks and benefits associated with modern hormone formulations.
- 2026 (The Current Study): Researchers utilizing the SWAN cohort have provided a more granular look at the demographic and temporal factors that influence MHT outcomes. By following over 2,700 women who experienced vasomotor symptoms (hot flashes and night sweats), the study provides evidence that race and timing play critical roles in how a woman’s body responds to hormonal intervention.
Supporting Data: Demographics and Disparities
The study’s demographic breakdown reveals a critical area of health equity. When researchers adjusted for race, the protective cardiovascular effect of MHT was notably pronounced in Black women (aHR 0.51), whereas no clear, statistically significant benefit was observed for participants of other racial backgrounds.
This finding is particularly relevant given that Black women often report higher rates of vasomotor symptoms and higher incidences of cardiovascular disease compared to other populations. While the researchers caution that these results should not be interpreted as a blanket recommendation for MHT to prevent heart disease, the disparity suggests that future clinical guidelines may need to be more tailored to the individual’s racial and physiological profile.
Furthermore, the study addressed the ongoing debate regarding the increased risk of breast cancer. The researchers observed an increased risk of breast cancer among MHT initiators (aHR 1.41) compared to non-initiators. This highlights the delicate balancing act that clinicians face: while MHT may provide relief for debilitating vasomotor symptoms—which affect up to 80% of women—and potentially lower CVD risk in specific windows, it carries other non-negligible risks that must be weighed in a personalized clinical setting.
Official Responses and Expert Commentary
The publication has sparked a productive dialogue among experts. In an accompanying commentary, Regina Castaneda, MD, and Stephanie Faubion, MD, MBA, of the Mayo Clinic, emphasized that while the findings are encouraging, they should be viewed with a degree of intellectual humility.
"The cardiovascular effects of MHT for those in the early stages of the menopause transition remain poorly characterized," the authors noted. A significant point of contention raised by the Mayo Clinic team is the heterogeneity of the hormone formulations included in the study. The researchers included systemic oral or transdermal estrogen, and even oral contraceptives, in their definition of MHT.
Castaneda and Faubion pointed out that oral contraceptives often contain higher doses of estrogen and synthetic progestins compared to standard postmenopausal MHT regimens. They suggested that the study might have been underpowered to detect significant differences based on the type of hormone therapy used, leaving a gap that future, more specialized research must fill.
Implications for Clinical Practice
For clinicians and their patients, the implications of this study are twofold. First, it reinforces the necessity of the "individualized approach." The era of applying one set of rules to all menopausal women is clearly over. Conversations about MHT must now be centered on the specific timing of the menopause transition, the patient’s personal health history, and the presence of vasomotor symptoms.
Second, the study provides a robust, if observational, foundation for reconsidering the potential cardiovascular benefits of early MHT initiation. However, the authors themselves were explicit: "Given the lack of consistent CVD benefit and the overall risk-benefit balance, these findings should not be used to support the use of MHT for CVD prevention."
In essence, MHT should be prescribed primarily for the management of menopause-related symptoms, such as hot flashes and night sweats, which can severely impact a woman’s quality of life. Any potential cardiovascular or skeletal benefits should be viewed as secondary, potential advantages that occur only within specific clinical parameters.
Moving Forward: The Need for Randomized Controlled Trials
While the SWAN cohort data is comprehensive, the researchers and commentators agree that this study is not the final word. Observational studies, no matter how well-structured as "target trial emulations," are always subject to potential residual confounding—factors that may not have been fully accounted for, such as lifestyle differences between women who choose to use hormone therapy and those who do not.
The scientific community is now calling for rigorous, randomized controlled trials (RCTs) that focus on younger women in the early stages of perimenopause. Such studies would need to isolate specific delivery routes (e.g., transdermal vs. oral) and specific hormone formulations to provide a clearer, more definitive roadmap for practitioners.
As it stands, the message to women is one of informed empowerment. The findings from Dr. El Khoudary and her colleagues offer a reprieve from the blanket fear that dominated the last twenty years. By engaging in open, data-driven conversations with their healthcare providers, women navigating the transition of menopause can now better evaluate whether MHT is the right tool to help them manage their symptoms and protect their long-term health.
